Personal view: Deaths in trials should always be reported

BMJ (Online)

Volumn 347, Issue 7917, 2013, Pages

  Schroll, Jeppe ^a  

^a University of Copenhagen   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; HEMOGLOBIN A1C; NATEGLINIDE; REPAGLINIDE; ROFECOXIB; SULFONYLUREA; TOLBUTAMIDE; ANTIDIABETIC AGENT; CARBAMIC ACID DERIVATIVE; PIPERIDINE DERIVATIVE; SULFONYLUREA DERIVATIVE;

ACCESS TO INFORMATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); DRUG FATALITY; DRUG INFORMATION; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPOGLYCEMIA; MANDATORY REPORTING; MEDICAL LITERATURE; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PRIORITY JOURNAL; PROTOCOL COMPLIANCE; PUBLICATION; ARTICLE; MORTALITY; STANDARD;

CARBAMATES; CLINICAL TRIALS AS TOPIC; HUMANS; HYPOGLYCEMIC AGENTS; MORTALITY; PIPERIDINES; SULFONYLUREA COMPOUNDS;

EID: 84880624216     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f4219     Document Type: Note

References (15)

1. Chan AW, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004;291:2457-65. (Pubitemid 38669189)
2. Rising K, Bacchetti P, Bero L. Reporting bias in drug trials submitted to the Food and Drug Administration: A review of publication and presentation. PLoS Med 2008;5:e217.
3. Williamson PR, Gamble C. Identification and impact of outcome selection bias in meta-analysis. Stat Med 2005;24:1547-61. (Pubitemid 40716353)
4. Hemmingsen B, Schroll JB, Lund SS, Wetterslev J, Gluud C, Vaag A, et al. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus. Cochrane Database Syst Rev [forthcoming].
5. Center for Drug Evaluation and Research. Approval package for Prandin tablets 20-741/S009. 2000. www.accessdata.fda.gov/drugsatfda-docs/nda/2000/ 020741-S009- PRANDIN-TABS-AP.pdf.
6. Wolffenbuttel BH, Landgraf R. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group. Diabetes Care 1999;22:463-7. (Pubitemid 29106906)
7. Madsbad S, Kilhovd B, Lagert I, Mustajoki P, Dejgaard A. Comparison between repaglinide and glipizide in type 2 diabetes mellitus: a 1-year multicentre study. Diabet Med 2001;18:395-401. (Pubitemid 32679389)
8. Marbury T, Huang WC, Strange P, Lebovitz H. Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res Clin Pract 1999;43:155-66. (Pubitemid 29202125)
9. University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II Mortality results. Diabetes 1970;19:789-830.
10. Owens DR. Repaglinide-Prandial glucose regulator: a new class of oral antidiabetic drugs. Diabet Med 1998;15(suppl 4):S28-36.
11. Owens DR, Zinman B, Bolli GB. Insulins today and beyond. Lancet 2001;358:739-46. (Pubitemid 32823407)
12. Nissen SE, Wolski K . Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71. (Pubitemid 46919772)
13. Curfman GD, Morrissey S, Drazen J. Expression of concern reaffirmed. N Engl J Med 2006;354:1193.
14. Psaty BM, Prentice RL. Minimizing bias in randomized trials: the importance of blinding. JAMA 2010;304:793-4.
15. Gøtzsche PC. Why we need easy access to all data from all clinical trials and how to accomplish it. Trials 2011;12:249.